arrow
D

Daniel D. Karp

university of texas system
H指数:55
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study (vol 40, pg 290, 2022)
2025-02-200
OAAI
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer

一项关于temsirolimus联合metformin治疗晚期或复发性子宫内膜癌的I期研究

2025-02-011
PRE
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations

talazoparib在具有BRCA1/2,DNA修复和PTEN改变的晚期癌症中的II期研究

2024-07-311
OAAI
The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
2024-05-020
PRE
NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations
2024-04-050
PRE
Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors
2024-03-220
PRE
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

avelumab联合utomilumab (4-1BB激动剂),PF-04518600 (OX40激动剂) 或放疗在晚期妇科恶性肿瘤患者中的1/2期试验

CANCER
IF5.1
2023-10-216
PRE
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors
2023-04-144
PRE
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer

selinexor和eribulin联合治疗晚期实体瘤和三阴性乳腺癌的1b期研究

CANCER
IF5.1
2023-04-043
PRE